drugset / Trial / NCT00301756

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

NCT00301756

Phase 2 Completed 32 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant potential tumors. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2006-09
Primary completion
2009-08
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Belinostat Small molecule Intravenous